Skip to main content
OpenTrials
Completed

NCT Number: NCT01493934

Development of a Fast Measurement Technique of Insulin Resistance in Human

Insulin resistance, characterised by a depressed cellular sensitivity to insulin in insulin-sensitive organs, is a central feature of the metabolic syndrome. In people with no diabetes mellitus, the presence of metabolic syndrome leads to an increase of mortality, whatever the cause, but, as a majority, cardiovascular diseases.

In patients with type 2 diabetes mellitus, the presence of a metabolic syndrome leads to an increase in major adverse cardiovascular events. The prevalence of metabolic syndrome is led to grow in a near future, because of the increase of diabetes mellitus and obesity prevalence.

Actually, there is no simple tool to measure insulin resistance. The gold standard technique remains the hyperinsulinemic euglycemic clamp. However, the complexity and length of this technique render it unsuitable for routine clinical use. Many methods or index have been proposed to assess insulin resistance in human, but none have shown enough relevance to be used in clinical use.

Within the investigators U877 INSERM team, the investigators previously performed in vivo biodistribution studies with 6-DIG (6-deoxy-6-iodo-D-glucose), a new tracer of glucose transport, radiolabelled with123 iodine, with and without insulin, on the one hand in genetically diabetic mice (db/db), consequently having a severe insulin resistance and in the other hand in rats with acquired insulin resistance after a "fructose diet".

The investigators have demonstrated that 6-DIG is able to identify in vivo slight glucose transport variations in insulin sensible organs. Then, the investigators developed a fast and simple imaging protocol with a small animal gamma camera, which allows the obtaining of an insulin resistance index for each organ, directly transferable to human.

The investigators project is to transfer to human this measurement technique, perfectly validated in animal.

The main goal of this monocentric phase I-II study is to evaluate the tolerance to the insulin resistance measurement technique with 6DIG scintigraphy, in healthy volunteers and in diabetic patients. The investigators plan to enrol 6 healthy volunteers and 6 type 2 diabetic patients.

The investigators secondary goals will be to evaluate feasibility and reproducibility of the measurement technique, to follow pharmacokinetic and to assess efficacy of 6-DIG to measure insulin resistance.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Type 2 Diabetes Mellitus Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Hyperinsulinism Insulin Resistance Metabolic Diseases Metabolic Syndrome Nutritional and Metabolic Diseases

Age range

35 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Service de Biophysique et Médecine Nucléaire, CHU de Grenoble

Grenoble, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy volunteers
  • Aged between 35 et 60 years old
  • Body mass index between 20 and 25
  • Waist measurement < 94 cm for men and < 80 cm for women
  • Normal basal glycemia, between 3,8 and 5,8 mmol/l
  • Normal basal insulinemia, between 3 and 13 μUI/ml
  • HbA1c < 6%
  • Total cholesterol < 2 g/l
  • LDL cholesterol < 1,6 g/l
  • HDL cholesterol 0,4 g/l for men and 0,5 g/l for women
  • Triglyceride level < 1,5 g/l
  • For women not menopausal since at last one year or not surgically sterilised:

On-going contraception, physical or hormonal, excepted local methods (spermicidal, diaphragm, condom, cape)

  • Type 2 diabetic patients
  • Aged between 35 et 60 years old
  • Stable type 2 diabetes mellitus: no ketoacidosis sign during last month
  • HbA1c between 6 and 8% during the 3 months before study inclusion
  • Monotherapy by metformin or diet only
  • For women not menopausal since at last one year or not surgically sterilised:
  • On-going contraception, physical or hormonal, excepted local methods (spermicidal, diaphragm, condom, cape)

Exclusion criteria

  • Diabetes mellitus previously known
  • Other on-going progressive illness
  • Psychiatric illness, needing a chronic treatment
  • Previous history of myocardial infarction, coronary artery disease, cardiac rhythm troubles, stroke, epilepsy, cranial trauma, pituitary surgery, disease likely to reduce the ability of absorption, diffusion or excretion of the radiotracer.
  • Severe hypertension defined by par SAP > 180 mmHg and/or DAP > 110 mmHg
  • Allergy to one of the components of the products used during the study
  • Nuclear medicine examination during the 30 days prior to study inclusion
  • Treatment likely to interfere with glucose metabolism
  • Alcohol or drug intoxication
  • Vegetarian or restrictive low-calory diet,
  • Pregnant, parturient or breast-feeding women,
  • Inappropriate way of life
  • Type 2 diabetic patients.
  • Previous history of myocardial infarction
  • Severe hypertension defined by par SAP > 180 mmHg and/or DAP > 110 mmHg
  • Previous history of coronary artery disease, cardiac rhythm troubles, stroke, epilepsy, cranial trauma, pituitary surgery, disease likely to reduce the ability of absorption, diffusion or excretion of the radiotracer.
  • Psychiatric illness, needing a chronic treatment
  • On-going insulin treatment
  • On-going treatment other than metformin, likely to interfere with glucose metabolism
  • Previous history of disease likely to reduce the ability of absorption, diffusion or excretion of the radiotracer
  • Allergy to one of the components of the products used during the study
  • Nuclear medicine examination during the 30 days prior to study inclusion
  • Alcohol or drug intoxication
  • Vegetarian or restrictive low-calory diet,
  • Pregnant, parturient or breast-feeding women,
  • Inappropriate way of life

Treatment and study plan

injection of 6-DIG

Drug

Unique injection dose of 92.5 MBq

Primary outcomes

  1. Change of glycemia

    Time frame: Before inclusion in clinical trial, Before radiotracer injection, After radiotracer injection (time: 30s, 1', 2',5',10',15',25', 1 hour, 2 hours, 4 hours, 8 hours, 24 hours)

    Assessment of tolerance to insulin resistance measurement technique with 6-DIG scintigraphy, in healthy volunteers

    • clinical tolerance to 6-DIG infusion
    • clinical and biological tolerance to insulin infusion
    • evaluation of dosimetry

Secondary outcomes

  1. insulinemia

    Time frame: Before inclusion in clinical trial, Before radiotracer injection, After radiotracer injection (time: 30s, 1', 2',5',10',15',25', 1 hour, 2 hours, 4 hours, 8 hours, 24 hours)

  2. clinical side effects

    Time frame: Before inclusion in clinical trial, Before radiotracer injection, After radiotracer injection (time: 30s, 1', 2',5',10',15',25', 1 hour, 2 hours, 4 hours, 8 hours, 24 hours)

    hypoglycemia symptoms

  3. dosimetry

    Time frame: during the 24 hours following injection of 6-DIG

    organs biodistribution of radioactivity

  4. insulin resistance

    Time frame: 0-15 minutes following 6-DIG infusion

    scintigraphic measurement of glucose transport in heart before and after infusion of insulin

Sponsors and collaborators

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Other Gov

Registry information

Official study title

Development of a Fast Measurement Technique of Insulin Resistance in Human, With 123-6-deoxy-6 Iodo-D-glucose, a New Tracer of Glucose Transport

Acronym: GLUCIMAG

Important dates

Study start
2010
Primary completion
2013
Study completion
2013
First posted
Dec 16, 2011
Registry last updated
Aug 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.